BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study tests a new medication for treatment of kidney cancer, called BEZ235. This
medication works by blocking several mechanisms that the cancer needs to grow and survive. By
blocking these mechanisms, the medication can thus suppress further growth of the cancer,
possibly kill cancer cells. Older kidney cancer medications (such as temsirolimus [Torisel®]
or everolimus [Afinitor®]) typically only block one mechanism in cancer cells, so the
investigators think that BEZ235 may work even better against kidney cancer.
The purpose of the first part of this study is to test the safety of giving BEZ235 at
different doses. The investigators are trying to find a safe dose of BEZ235 and want to find
out what effects, good and/or bad, it has on the patient and the cancer.